Atomo Diagnostics Ltd (ASX:AT1)

Half Year 2025 Atomo Diagnostics Ltd Earnings Call Transcript

Mar 2, 2025 / 12:00 AM GMT

Release Date Price: A$0.018

Transcript

Key Points

Positve

Atomo Diagnostics Ltd (ASX:AT1) reported a 7% increase in top-line revenue, reaching over $2 million for the period.
The company maintained a consistent quality of margin at 45%, driven by improved customer demand, particularly in the HIV domestic Australian market.
Atomo Diagnostics Ltd (ASX:AT1) has successfully entered the Australian market with its HIV self-test product, now sold in over 300 pharmacies.
The company has a diversified product mix and is not dependent on any single product or country for revenue, with sales coming from various regions worldwide.
Atomo Diagnostics Ltd (ASX:AT1) has a strong patent portfolio, including 5 valuable patents in the US market, supporting its long-term business strategy.

Negative

The company experienced a cash burn of just under $800,000 over the six-month period.
There is uncertainty regarding the impact of recent US aid announcements on LMIC procurement agencies, which could affect future revenue.
Atomo Diagnostics Ltd (ASX:AT1) is still working towards profitability and has not yet reached break-even.
The company faces challenges in expanding its product offerings, with some products requiring additional funding and regulatory approvals.
There is a dependency on securing partnerships and licensing agreements to support the commercialization of new products, which may pose risks if not achieved.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AT1.AX - Atomo Diagnostics Ltd
Half Year 2025 Atomo Diagnostics Ltd Earnings Call
Mar 03, 2025 / 12:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, everyone. My name is John Kelly. I'm the CEO and managing director of Atomo Diagnostics.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Hi, Ron. I'm Susie. I'm the financial controller at Automa Diagnostics.

--------------------------------------------------------------------------------
Unidentified_1 [3]
--------------------------------------------------------------------------------
Thank you for joining us this morning for our half year FY 2025 results. We put the results out on Friday to market, and we wanted today to take this

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.